Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Beta-lactam antibiotics (BLAs) have been mainstays in treating bacterial infections since 1929.
• The rise of beta-lactamases has significantly reduced the effectiveness of current BLAs.
• ESKAPE pathogens represent a major global health threat due to multidrug resistance.

Purpose of the Study:

• To review existing and novel BLAs and their mechanisms.
• To provide an update on beta-lactamase inhibitors (BLIs) effective against ESKAPE pathogens.
• To discuss emerging alternative therapies for combating antimicrobial resistance.

Main Methods:

• Literature review of scientific publications on beta-lactam antibiotics and resistance mechanisms.
• Analysis of current research on beta-lactamase inhibitors (BLIs).
• Exploration of alternative therapeutic strategies including bacteriophages, antimicrobial peptides, nanoparticles, CRISPR-Cas, and vaccination.

Main Results:

• BLAs remain a significant class of antibiotics, but resistance is widespread.
• Development of BLIs is crucial for restoring BLA efficacy against resistant bacteria.
• Several novel approaches show promise in addressing antimicrobial resistance.

Conclusions:

• Combating antimicrobial resistance requires a multifaceted approach, including the development of new BLIs and alternative therapies.
• Continued research into novel strategies is essential to address the growing threat of multidrug-resistant pathogens.
• The review highlights the urgent need for innovative solutions to preserve the effectiveness of antimicrobial drugs.